Moreover, MLL frequently hosts international research cooperation directly: For instance through exchange programs, our test procedures and data repositories, but also by allowing guest researchers to shadow the work of our facility and by sitting on national and international work groups.

We also support research institutions around the world to produce new insight in the field of leukemia diagnostics and emergence, as well as in the rollout of new procedures and applications for routine diagnostics in the facilities themselves.


Our research findings are published in international, peer-reviewed journals and feature in conference talks and lectures, as well as in poster presentations and at scientific events.

Baer C, Dicker F, Kern W, Haferlach T, Haferlach C. Genetic characterization of MYD88 mutated lymphoplasmacytic lymphoma in comparison to MYD88 mutated chronic lymphocytic leukemia. Leukemia. 2017;31(6):1355-1362.

Bellos F, Kern W. Flow cytometry in the diagnosis of myelodysplastic syndromes (MDS) and the value of myeloid nuclear differentiation antigen (MNDA). Cytometry B Clin Cytom. 2017;92(3):200-206.

Chien W, Sun QY, Ding LW, Mayakonda A, Takao S, Liu L, Lim SL, Tan KT, Garg M, De Sousa Maria Varela A, Xiao J, Jacob N, Behrens K, Stocking C, Lill M, Madan V, Hattori N, Sigal G, Ogawa S, Wakita S, Ikezoe T, Shih LY, Alpermann T, Haferlach T, Yang H, Koeffler HP. Diagnosis and relapse: Cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD. Leukemia. 2017;31(3):762-766.

Durham BH, Getta B, Dietrich S, Taylor J, Won H, Bogenberger JM, Scott S, Kim E, Chung YR, Chung SS, Hüllein J, Walther T, Wang L, Lu SX, Oakes CC, Tibes R, Haferlach T, Taylor BS, Tallman MS, Berger MF, Park JH, Zenz T, Abdel-Wahab O. Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood. 2017;130(14):1644-1648.

Fasan A, Haferlach C, Perglerovà K, Kern W, Haferlach T. Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse. Haematologica. 2017;102(6):e222-e224.

Francke S, Mies A, Meggendorfer M, Oelschlaegel U, Balaian E, Gloaguen S, Haferlach T, Ehninger G, Bornhäuser M, Platzbecker U. Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2. Leuk Lymphoma. 2017;58(5):1271-1272.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398-2406.

Jann JC, Nowak D, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Palme I, Xanthopoulos C, Fabarius A, Platzbecker U, Giagounidis A, Götze K, Letsch A, Haase D, Schlenk R, Bug G, Lübbert M, Ganser A, Germing U, Haferlach C, Hofmann WK, Mossner M. Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA. J Med Genet. 2017;54(9):640-650.

Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lotfi S, Maywald O, Mielke S, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Panse J, Vieler T, Hofmann WK, Haferlach T, Haferlach C, Fabarius A, Hochhaus A, Cross NCP, Reiter A, Metzgeroth G. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Ann Hematol. 2017;96(9):1463-1470.

Jawhar M, Schwaab J, Meggendorfer M, Naumann N, Horny HP, Sotlar K, Haferlach T, Schmitt K, Fabarius A, Valent P, Hofmann WK, Cross NCP, Metzgeroth G, Reiter A. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica. 2017 Jun;102(6):1035-1043.

1 / 3